Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
20.30
-0.12 (-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
35
36
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 14, 2023
Via
Benzinga
2 Top Growth Stocks to Buy With $500
↗
September 14, 2023
No need to break the bank to invest in stocks.
Via
The Motley Fool
Insiders Are Buying These 2 Stocks
September 08, 2023
Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment.
Via
MarketBeat
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
September 07, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
↗
August 23, 2023
An upcoming data readout could fuel another rally in the biotech's shares.
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
↗
August 03, 2023
Via
Benzinga
Earnings Preview: Sarepta Therapeutics
↗
August 01, 2023
Via
Benzinga
2 Biotech Growth Stocks I'd Buy Right Now
↗
July 27, 2023
Both drugmakers seem to have a bright future ahead.
Via
The Motley Fool
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
↗
August 22, 2023
Helping save and improve patients' lives in novel ways can be a lucrative activity.
Via
The Motley Fool
Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
↗
August 15, 2023
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.
Via
Benzinga
Where Sarepta Therapeutics Stands With Analysts
↗
July 14, 2023
Via
Benzinga
What 25 Analyst Ratings Have To Say About Sarepta Therapeutics
↗
June 23, 2023
Via
Benzinga
Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy
↗
June 22, 2023
Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys.
Via
Investor's Business Daily
$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying
↗
August 14, 2023
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
↗
August 02, 2023
SRPT earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
August 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
July 26, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Biotech Stocks to Sell Before They Damage Your Portfolio
↗
July 12, 2023
With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point.
Via
InvestorPlace
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
July 05, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
July 03, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
↗
June 30, 2023
While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit.
Via
The Motley Fool
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
June 27, 2023
Recent events surrounding Sarepta Therapeutics highlights the unpredictability of the biotech industry and its appropriateness solely for high-risk investors.
Via
MarketBeat
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 23, 2023
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
↗
June 23, 2023
Via
Benzinga
Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday
↗
June 23, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)...
Via
Benzinga
Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy
↗
June 22, 2023
The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged...
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
